Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes.

The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use.

Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments.

Dr. William Makis's Recommended Ivermectin Dosages for Cancer
Key Ivermectin Dosage GuidelinesIvermectin is typically taken orally with a fatty meal for better absorption. The protocol suggests cycles of 6 days on/1 day off, or 3 weeks on/1 week off, over 3–12 months, with long-term maintenance possible at lower doses. Higher doses are reported as safe in his observations, but monitor for side effects like gastrointestinal issues or transient visual disturbances.
  • Low-grade (e.g., early-stage, remission maintenance, or prophylaxis): Dosage of 0.5 mg/kg, taken 3 times per week (e.g., Mon/Wed/Fri). Suitable for prevention or stable cases; complements other protocol elements.
  • Intermediate-grade (e.g., moderately progressive or challenging cases): Dosage of 0.5–1 mg/kg, taken 3 times per week, or daily if needed. Escalate based on response; often combined with benzimidazoles for synergy.
  • High-grade (e.g., aggressive, metastatic, or turbo cancers): Dosage of 1–2 mg/kg (up to 2.5 mg/kg in severe cases), taken daily. For advanced disease; case reports show remissions in 2–6 months when used adjunctively.

Real Patient Outcomes from Dr. Makis's Practice (2025 Cases)

All cases below are from Dr. Makis's 2025 testimonials (X
@MakisMD
& Substack):
  1. 53 year old Canadian woman – Stage 2 Triple Negative Breast Cancer (7.8 cm tumor) → Cancer Free in 7 months (Dec 2024–Jul 2025).
  2. 58 year old California CEO – Recurrent Stage 4 Kidney Cancer → Dying tumors in 10 weeks
  3. 70 year old Morocco man – Stage 4 Lymphoma → Complete remission in 2.5 months
  4. 39 year old Texas woman – Stage 4 Colon with liver mets → CEA from 441 → 21.9 in 4 months
  5. 42 year old woman – Stage 4 Kidney Cancer (lungs/liver/shoulder mets) → NED after 1 year
  6. 53 year old UK woman – Stage 4 Breast (12 cm tumor) → 68% shrinkage in 2 months.
  7. Stage 3 ovarian cancer: 12 mg daily (approx. 0.2 mg/kg for a 60 kg person) with chemotherapy led to complete resolution in 2 months.
  8. 83-year-old - Stage 3 follicular lymphoma: 1 mg/kg daily achieved near-total remission in 6 months.
  9. 54-year-old - Recurrent prostate cancer: 1.5 mg/kg daily resulted in remission in 4 months.
Success rate in Makis-coached Stage 4 patients achieving major response or NED now consistently >65–70% when protocol is followed rigorously.Read More: Fenbendazole Cancer Success Stories: 400+ Case Reports Compilation (2026 Edition)

Broader Protocol Context

Makis's full protocol includes 7 components for synergy, but ivermectin is a core element. Other key parts (Hybrid orthomolecular protocol 2024):

  • Benzimidazoles (e.g., mebendazole): 200–1,500 mg/day depending on grade, or fenbendazole 222–1,000 mg 3–6x/week.
  • Vitamin D3: 2,000–50,000 IU/day to reach 80 ng/mL blood levels.
  • IV Vitamin C: 1.5 g/kg, 2–3x/week for intermediate/high-grade.
  • Ketogenic diet: Restrict carbs to induce ketosis (glucose-ketone index ≤2.0).
Precautions: 
  • Source from reputable pharmacies; avoid if pregnant or with certain contraindications.
  • Evidence is anecdotal and preclinical—large trials are lacking.
  • Never self treat - need medical supervision to ensure safety first.

Should You Combine Mebendazole with Fenbendazole? 2025 Evidence

Yes, under guidance—synergy potential high.
  • Preclinical: CI<1 with analogs; 80-90% xenograft reduction (Anticancer Res).
  • Trials: Indirect—mebendazole + temozolomide (EClinicalMedicine 2022); fenben untested.
  • Cases: 100+ Stage 4 (William Makis): Pancreatic 70-87% shrink (meben AM + fenben PM); breast NED in 6 weeks (combo + ivermectin).
  • Risks: Liver strain; GI progression risk (CancerChoices). Monitor weekly Liver Function Tests. 
Read more: Fenbendazole vs Mebendazole for Cancer: What is the Difference? (December 2025 Edition)


Disclaimers:
  • Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
  • Please do not consider this guide as personal medical advice, but as a recommendation for use with professional providers. Consult with your doctor and discuss with her/him. Our aim here isn't to replace your doctors' advice. It is intended as a sharing of knowledge and information. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle. Any potential treatment—whether conventional or complementary—must be evaluated on a case-by-case basis, with careful consideration of the benefit-risk ratio to ensure both safety and efficacy.
  • The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research, consult with relevant medical professionals before attempting to self-treat for any condition.
  • Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative. 
  • Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
  • While the term 'alternative' might imply opposition to conventional oncology, we prefer 'complementary,' 'integrated,' 'holistic' or 'foundational'. These terms better reflect the role of these strategies as part of a personalized value-added menu of strategies, ensuring the most effective and safe solutions for patients.
  • Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing. By combining conventional cancer management with root-cause resolution, this model creates a path to sustained recovery and resilience. 

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 350 Patients (2025)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2025, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or cancer treatment. There are no completed randomized controlled human clinical trials demonstrating its safety or efficacy against cancer. All human evidence is anecdotal, from case...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Best Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discover...
Read more

Fenbendazole and Cancer: What Does the Latest Research Say?

By Editorial Team
Image
Abstract Cancer continues to pose a significant global health burden, particularly with the rise of aggressive and treatment-resistant malignancies such as triple-negative breast cancer, pancreatic adenocarcinoma, and glioblastoma. In response to the limitations of current therapies, there is growing interest in the repurposing of antiparasitic agents—specifically fenbendazole—for oncological applications. This review synthesizes recent preclinical and emerging clinical evidence on the anticancer mechanisms and therapeutic potential of this drug. Fenbendazole, a benzimidazole compound, demonstrates anticancer activity through microtubule destabilization, cell cycle arrest, and inhibition of glucose metabolism, though its clinical application is challenged by poor solubility and bioavailability. Despite promising laboratory and anecdotal clinical results, robust randomized controlled trials are lacking, and regulatory approval for cancer indications remains limited. The review highlight...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...
Read more